Technical Analysis for NVCR - NovoCure Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Stochastic Sell Signal | Bearish | 1.98% | |
| 20 DMA Support | Bullish | 1.98% | |
| Wide Range Bar | Range Expansion | 1.98% | |
| Doji - Bullish? | Reversal | 1.98% | |
| Weak + Overbought | Other | 1.98% | |
| Outside Day | Range Expansion | 1.98% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 6 hours ago |
| Down 3% | about 9 hours ago |
| Down 2 % | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
| Down 1% | about 9 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
Sector: Healthcare
Industry: Medical Instruments & Supplies
Keywords: Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Blastoma Small Cell Lung Cancer Glioblastoma Brain Tumor Solid Tumor Cancers Aging Associated Diseases Metastases Brain Cancer Mesothelioma
Classification
Sector: Healthcare
Industry: Medical Instruments & Supplies
Keywords: Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Blastoma Small Cell Lung Cancer Glioblastoma Brain Tumor Solid Tumor Cancers Aging Associated Diseases Metastases Brain Cancer Mesothelioma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.1 |
| 52 Week Low | 10.87 |
| Average Volume | 1,552,841 |
| 200-Day Moving Average | 15.50 |
| 50-Day Moving Average | 19.95 |
| 20-Day Moving Average | 17.88 |
| 10-Day Moving Average | 18.74 |
| Average True Range | 1.06 |
| RSI (14) | 54.55 |
| ADX | 19.54 |
| +DI | 18.50 |
| -DI | 22.54 |
| Chandelier Exit (Long, 3 ATRs) | 16.19 |
| Chandelier Exit (Short, 3 ATRs) | 19.04 |
| Upper Bollinger Bands | 19.81 |
| Lower Bollinger Band | 15.95 |
| Percent B (%b) | 0.79 |
| BandWidth | 21.60 |
| MACD Line | -0.01 |
| MACD Signal Line | -0.21 |
| MACD Histogram | 0.2034 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.29 | ||||
| Resistance 3 (R3) | 21.15 | 20.25 | 20.91 | ||
| Resistance 2 (R2) | 20.25 | 19.68 | 20.32 | 20.78 | |
| Resistance 1 (R1) | 19.64 | 19.32 | 19.19 | 19.78 | 20.66 |
| Pivot Point | 18.74 | 18.74 | 18.52 | 18.81 | 18.74 |
| Support 1 (S1) | 18.13 | 18.17 | 17.68 | 18.27 | 17.38 |
| Support 2 (S2) | 17.23 | 17.81 | 17.30 | 17.26 | |
| Support 3 (S3) | 16.62 | 17.23 | 17.13 | ||
| Support 4 (S4) | 16.76 |
